Search
Blonanserin
go.drugbank.com/drugs/DB09223InvestigationalIt offers improved tolerability as it lacks side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. … Blonanserin is an atypical antipsychotic approved in Japan in January, 2008.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesStreptococcus pneumoniae type 1 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10319ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 1 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 1 of *Streptococcus pneumoniae*.
Streptococcus pneumoniae type 6b capsular polysaccharide antigen
go.drugbank.com/drugs/DB10324ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 6b capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 6b of *Streptococcus pneumoniae*
Streptococcus pneumoniae type 7f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10325ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 7f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 7f of *Streptococcus pneumoniae*
Streptococcus pneumoniae type 9n capsular polysaccharide antigen
go.drugbank.com/drugs/DB10327ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 9n capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 9n of *Streptococcus pneumoniae*
Streptococcus pneumoniae type 12f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10331ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 12f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 12f of *Streptococcus pneumoniae
Streptococcus pneumoniae type 19f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10336ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 19f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 19f of *Streptococcus pneumoniae
Streptococcus pneumoniae type 33f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10341ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 33f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 33f of *Streptococcus pneumoniae
Kanamycin
go.drugbank.com/drugs/DB01172ApprovedInvestigationalVet approvedWithdrawnKanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections.
Synonyms: Kanamycin ACategories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic IndexOzanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigational[A189336] In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard … Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates